Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Danazol therapy for cyclic thrombocytopenia.

R Rocha1, L Horstman, Y S Ahn

  • 1Department of Medicine, U.S. Veteran Administration Hospital, Miami, Florida.

American Journal of Hematology
|February 1, 1991
PubMed
Summary

Cyclic thrombocytopenia, a rare bleeding disorder, showed significant improvement with danazol therapy. This treatment offers lasting remission for patients refractory to other therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Fernández GC et al., "Beyond diet: the role of awareness and socioeconomic status in metabolic dysfunction-associated steatotic liver disease".

Revista de gastroenterologia de Mexico (English)·2026
Same author

Prehospital seizure management in the paediatric patient: a multicentre emergency department study.

Neurologia·2026
Same author

Defining Standard Data Reporting in Pelvic Exenterations for Non-Rectal Cancers: A Systematic Review of Current Data Reporting.

Cancers·2025
Same author

Metabolic dysfunction-associated steatotic liver disease and dietary intake characteristics in children and adolescents: A cross-sectional study.

Revista de gastroenterologia de Mexico (English)·2025
Same author

The economic burden of overweight and obesity in Brazil: perspectives for the Brazilian Unified Health System.

Public health·2022
Same author

OPTN/SRTR 2020 Annual Data Report: COVID.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2022

Area of Science:

  • Hematology
  • Immunology

Background:

  • Cyclic thrombocytopenia is a rare disorder with unpredictable, severe bleeding episodes.
  • Current treatments for cyclic thrombocytopenia have yielded disappointing results.
  • The pathophysiology of cyclic thrombocytopenia remains largely unknown.

Observation:

  • A patient with a 7-year history of cyclic thrombocytopenia, refractory to multiple treatments, experienced oscillations in platelet counts.
  • Platelet-associated antibodies were positive, and platelet survival time was shortened.
  • Danazol therapy was initiated for the patient's refractory cyclic thrombocytopenia.

Findings:

  • Danazol therapy led to significantly higher nadir platelet counts within 2 months.
  • Petechiae resolved within 9 months of danazol treatment.

Related Experiment Videos

  • While platelet-associated IgG remained positive initially, platelet counts stabilized, and remission was achieved after 3.5 years of treatment.

    • Implications:

    • Danazol therapy may offer a promising and lasting treatment option for cyclic thrombocytopenia.
    • This case suggests danazol's efficacy in managing refractory cases of cyclic thrombocytopenia.
    • Further research into danazol's role in treating rare platelet disorders is warranted.